November 16, 2014

Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis

.   .   

In this RCT, patients with ANCA-associated vasculitis who achieved complete remission after a cyclophosphamide-glucocorticoid regimen were randomly assigned to receive intermittent rituximab (days 0 and 14 and at months 6, 12, and 18) or daily azathioprine until month 22.  Major relapse was less common in the rituximab arm than the azathioprine arm (5% vs 29%) with a hazard ratio for relapse of 6.61; 95% confidence interval, 1.56 to 27.96; P=0.002). There were no differences in adverse events between arms.

Related Articles:

Vasculitis